Literature DB >> 8228639

Characterization of a hamster melanoma-associated ganglioside antigen as 7-O-acetylated disialoganglioside GD3.

S Ren1, T Ariga, J N Scarsdale, Y Zhang, A Slominski, P O Livingston, G Ritter, Y Kushi, R K Yu.   

Abstract

We previously reported a hamster animal model of melanoma in which the tumor tissue expresses gangliosides GM3, GD3, and O-acetyl GD3. This ganglioside pattern is similar to that in human melanomas (Ren, S., A. Slominski, and R. K. Yu. 1989 Cancer Res. 49: 7051). In this study, we isolated and purified these gangliosides using chloroform-methanol extraction, Folch partition, chromatographies on DEAE-Sephadex A-25, and Iatrobeads columns. The yields of gangliosides GM3, GD3, and O-acetyl GD3 were 44.1 mg, 19.6 mg, and 9 mg per 100 g of Ma melanotic melanoma tissues, respectively. The structures of these gangliosides were characterized by periodate oxidation, gas chromatographic (GC) analysis, fast-atom bombardment-mass spectrometry (FAB-MS), and nuclear magnetic resonance (NMR) studies. The structure of hamster melanoma O-acetyl GD3 is different from the 9-O-acetyl GD3 previously reported in human melanoma. The major fatty acids of this ganglioside are C16:0, C18:0, C20:0, C22:0, and C24:0 and the long-chain base is C18-sphingosine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8228639

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  8 in total

1.  Identification of 9-O-acetyl-N-acetylneuraminic acid (Neu5,9Ac2) as main O-acetylated sialic acid species of GD2 in breast cancer cells.

Authors:  Sumeyye Cavdarli; Justine H Dewald; Nao Yamakawa; Yann Guérardel; Mickaël Terme; Jean-Marc Le Doussal; Philippe Delannoy; Sophie Groux-Degroote
Journal:  Glycoconj J       Date:  2019-01-05       Impact factor: 2.916

2.  1H NMR ganglioside ceramide resonance region on the differential diagnosis of low and high malignancy of brain gliomas.

Authors:  V Lombardi; L Valko; M Valko; A Scozzafava; H Morris; M Melnik; J Svitel; M Budesinský; J Pelnár; J Steno; T Liptaj; L Zalibera; J Budinská; J Zlatos; A Giuliani; L Mascolo; D Leibfritz; A Troncone; F Marzullo; M Mazur; J Klener; E Zverina
Journal:  Cell Mol Neurobiol       Date:  1997-10       Impact factor: 5.046

3.  Characterization of novel mono-O-acetylated GM3s containing 9-O-acetyl sialic acid and 6-O-acetyl galactose in equine erythrocytes.

Authors:  Y Yachida; K Tsuchihashi; S Gasa
Journal:  Glycoconj J       Date:  1996-04       Impact factor: 2.916

4.  Unique disialosyl gangliosides from salmon kidney: characterization of V3alphaFuc, IV3betaGalNAc, II3(alphaNeuAc)2-Gg4Cer and its analogue with 4-O-acetyl-N-acetylneuraminic acid.

Authors:  Yukio Niimura; Ineo Ishizuka
Journal:  Glycoconj J       Date:  2006-11       Impact factor: 3.009

5.  O-acetylation of GD3: an enigmatic modification regulating apoptosis?

Authors:  Helen Y Chen; Ajit Varki
Journal:  J Exp Med       Date:  2002-12-16       Impact factor: 14.307

Review 6.  Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy.

Authors:  Julien Fleurence; Sophie Fougeray; Meriem Bahri; Denis Cochonneau; Béatrice Clémenceau; François Paris; Andras Heczey; Stéphane Birklé
Journal:  J Immunol Res       Date:  2017-01-05       Impact factor: 4.818

7.  Binding specificity of influenza C-virus to variably O-acetylated glycoconjugates and its use for histochemical detection of N-acetyl-9-O-acetylneuraminic acid in mammalian tissues.

Authors:  G Harms; G Reuter; A P Corfield; R Schauer
Journal:  Glycoconj J       Date:  1996-08       Impact factor: 2.916

Review 8.  Transplantable Melanomas in Hamsters and Gerbils as Models for Human Melanoma. Sensitization in Melanoma Radiotherapy-From Animal Models to Clinical Trials.

Authors:  Martyna Śniegocka; Ewa Podgórska; Przemysław M Płonka; Martyna Elas; Bożena Romanowska-Dixon; Małgorzata Szczygieł; Michał A Żmijewski; Mirosława Cichorek; Anna Markiewicz; Anna A Brożyna; Andrzej T Słominski; Krystyna Urbańska
Journal:  Int J Mol Sci       Date:  2018-04-01       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.